Literature DB >> 29370351

Combined Hyperglycemia- and Hyperinsulinemia-Induced Insulin Resistance in Adipocytes Is Associated With Dual Signaling Defects Mediated by PKC-ζ.

Huogen Lu1,2, Elena Bogdanovic1,2,3, Zhiwen Yu1,2, Charles Cho1,3, Lijiang Liu1,2, Karen Ho1,2, June Guo3, Lucy S N Yeung3, Reiner Lehmann4, Harinder S Hundal5, Adria Giacca3, I George Fantus1,2,3.   

Abstract

A hyperglycemic and hyperinsulinemic environment characteristic of type 2 diabetes causes insulin resistance. In adipocytes, defects in both insulin sensitivity and maximum response of glucose transport have been demonstrated. To investigate the molecular mechanisms, freshly isolated rat adipocytes were incubated in control (5.6 mM glucose, no insulin) and high glucose (20 mM)/high insulin (100 nM) (HG/HI) for 18 hours to induce insulin resistance. Insulin-resistant adipocytes manifested decreased sensitivity of glucose uptake associated with defects in insulin receptor substrate (IRS)-1 Tyr phosphorylation, association of p85 subunit of phosphatidylinositol-3-kinase, Akt Ser473 and Thr308 phosphorylation, accompanied by impaired glucose transporter 4 translocation. In contrast, protein kinase C (PKC)-ζ activity was augmented by chronic HG/HI. Inhibition of PKC-ζ with a specific cell-permeable peptide reversed the signaling defects and insulin sensitivity of glucose uptake. Transfection of dominant-negative, kinase-inactive PKC-ζ blocked insulin resistance, whereas constitutively active PKC-ζ recapitulated the defects. The HG/HI incubation was associated with stimulation of IRS-1 Ser318 and Akt Thr34 phosphorylation, targets of PKC-ζ. Transfection of IRS-1 S318A and Akt T34A each partially corrected insulin signaling, whereas combined transfection of both completely normalized insulin signaling. In vivo hyperglycemia/hyperinsulinemia in rats for 48 hours similarly resulted in activation of PKC-ζ and increased phosphorylation of IRS-1 Ser318 and Akt Thr34. These data indicate that impairment of insulin signaling by chronic HG/HI is mediated by dual defects at IRS-1 and Akt mediated by PKC-ζ.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29370351      PMCID: PMC5939637          DOI: 10.1210/en.2017-00312

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  56 in total

1.  Protein kinase Czeta is a negative regulator of protein kinase B activity.

Authors:  R P Doornbos; M Theelen; P C van der Hoeven; W J van Blitterswijk; A J Verkleij; P M van Bergen en Henegouwen
Journal:  J Biol Chem       Date:  1999-03-26       Impact factor: 5.157

Review 2.  Critical nodes in signalling pathways: insights into insulin action.

Authors:  Cullen M Taniguchi; Brice Emanuelli; C Ronald Kahn
Journal:  Nat Rev Mol Cell Biol       Date:  2006-02       Impact factor: 94.444

3.  A role for protein phosphatase 2A-like activity, but not atypical protein kinase Czeta, in the inhibition of protein kinase B/Akt and glycogen synthesis by palmitate.

Authors:  R Cazzolli; L Carpenter; T J Biden; C Schmitz-Peiffer
Journal:  Diabetes       Date:  2001-10       Impact factor: 9.461

4.  Free fatty acid-induced inhibition of glucose and insulin-like growth factor I-induced deoxyribonucleic acid synthesis in the pancreatic beta-cell line INS-1.

Authors:  S P Cousin; S R Hügl; C E Wrede; H Kajio; M G Myers; C J Rhodes
Journal:  Endocrinology       Date:  2001-01       Impact factor: 4.736

Review 5.  Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.

Authors:  G Boden
Journal:  Diabetes       Date:  1997-01       Impact factor: 9.461

6.  Mechanism of activation of protein kinase B by insulin and IGF-1.

Authors:  D R Alessi; M Andjelkovic; B Caudwell; P Cron; N Morrice; P Cohen; B A Hemmings
Journal:  EMBO J       Date:  1996-12-02       Impact factor: 11.598

7.  Regulation of protein kinase C zeta by PI 3-kinase and PDK-1.

Authors:  M M Chou; W Hou; J Johnson; L K Graham; M H Lee; C S Chen; A C Newton; B S Schaffhausen; A Toker
Journal:  Curr Biol       Date:  1998-09-24       Impact factor: 10.834

8.  Muscle-specific knockout of PKC-lambda impairs glucose transport and induces metabolic and diabetic syndromes.

Authors:  Robert V Farese; Mini P Sajan; Hong Yang; Pengfei Li; Steven Mastorides; William R Gower; Sonali Nimal; Cheol Soo Choi; Sheene Kim; Gerald I Shulman; C Ronald Kahn; Ursula Braun; Michael Leitges
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

9.  Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications.

Authors:  T S Lee; K A Saltsman; H Ohashi; G L King
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

10.  Protein kinase Czeta mediates insulin-induced glucose transport through actin remodeling in L6 muscle cells.

Authors:  Li-Zhong Liu; Hai-Lu Zhao; Jin Zuo; Stanley K S Ho; Juliana C N Chan; Yan Meng; Fu-De Fang; Peter C Y Tong
Journal:  Mol Biol Cell       Date:  2006-03-08       Impact factor: 4.138

View more
  4 in total

1.  Metabolism Score for Visceral Fat (METS-VF): A New Predictive Surrogate for CKD Risk.

Authors:  Ling Feng; Tong Chen; Xuan Wang; Chongxiang Xiong; Jianhui Chen; Shiquan Wu; Jing Ning; Hequn Zou
Journal:  Diabetes Metab Syndr Obes       Date:  2022-07-29       Impact factor: 3.249

2.  Metformin regulates atrial SK2 and SK3 expression through inhibiting the PKC/ERK signaling pathway in type 2 diabetic rats.

Authors:  Chang-He Liu; Na Hua; Xi Fu; Yi-Long Pan; Bin Li; Xiao-Dong Li
Journal:  BMC Cardiovasc Disord       Date:  2018-12-13       Impact factor: 2.298

Review 3.  Conventional protein kinase C in the brain: repurposing cancer drugs for neurodegenerative treatment?

Authors:  Gema Lordén; Alexandra C Newton
Journal:  Neuronal Signal       Date:  2021-10-08

Review 4.  Role of c-Jun N-terminal Kinase (JNK) in Obesity and Type 2 Diabetes.

Authors:  Justin Hou Ming Yung; Adria Giacca
Journal:  Cells       Date:  2020-03-13       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.